Navigation Links
Benda Pharmaceutical Files Amendment To Form S-1
Date:5/6/2008

WUHAN, Hubei, China, May 6 /Xinhua-PRNewswire-FirstCall/ -- Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today filed an amendment to the Company's Form S-1 application with the Securities and Exchange Commission ("SEC"). The amendment covers the resale by selling stockholders of up to 17,880,936 shares of common stock, $.001 par value, which includes:

1. 2,106,561 shares of common stock; and

2. 15,774,375 shares of common stock based on 150% of the common stock

issuable upon exercise of outstanding warrants issued at an exercise

price of $0.555 per share in conjunction with the private placements

completed on November 15, 2006 and April 5, 2007.

Mr. Charles Wan, Chief Executive Officer of Benda Pharmaceutical, stated, "We are pleased to file the amendment which takes us one step further to completing our S-1 registration."

Additional information regarding this registration can be found in the Company's Registration Statement on Form S-1/A, as filed with the SEC on May 5, 2008, which can be viewed at http://www.sec.gov .

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.

Safe Harbor Statement

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of acti
'/>"/>

SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
3. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
4. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
5. Shengtai Pharmaceutical, Inc. Appoints New CFO
6. DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania
7. Poniard Pharmaceuticals Announces Upcoming Conference Participation
8. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
11. Biopharmaceutical Alliances: Forging Partnerships That Work
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... at the University of Central Florida have developed a ... more sensitive tool to detect pathogens associated with inflammatory ... nanoparticle-based technique also may be used for detection of ... they hide deep in human tissue and are able ...
... 2012 Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company ... offer shares of its common stock and warrants to purchase ... The offering is subject to market and other conditions, and ... the offering may be completed, or as to the actual ...
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
Cached Biology Technology:UCF scientists use nanotechnology to hunt for hidden pathogens 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 3UK company to demonstrate their commercially effective graphene production process 2
(Date:7/8/2014)... OhioThe future health of the world,s coral reefs and ... on the ability of one tiny symbiotic sea creature ... of algae it cooperates with. , In the first ... University discovered that coralstiny reef-forming animals that live symbiotically ... of heat stress, called "bleaching," when they keep large ...
(Date:7/8/2014)... Think of your next exercise workout as a "fun run" or ... of it as exercise or as a workout and you,ll later ... findings from the Cornell Food and Brand Lab study involved two ... a small lake and were either told it was going to ... the first study, 56 adults completed their walk and were then ...
(Date:7/8/2014)... NY, July 8, 2014Novel oligonucleotide-based drugs in development ... diseases. A group of industry and regulatory scientists ... recommendations for evaluating the pharmacological safety of oligonucleotide ... Acid Therapeutics , a peer-reviewed journal from Mary ... on the Nucleic Acid Therapeutics ...
Breaking Biology News(10 mins):For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... issue of G&D report on the discovery of ... The studies from Drs. Alexander Stark and Manolis ... Lai (MSKCC) and colleagues, both reveal that antisense ... the novel miRNA precursor mir-iab-8, which is processed ...
... doctors treating life-threatening emergencies such as allergy attacks may give ... Adrenaline is stored in salt water in glass ampoules ... The amount of adrenaline contained in the ampoule is usually ... per 1 mL of salt water) and a ratio (1 ...
... team at Weill Cornell Medical College in New York City ... production of an immune system cytokine called interleukin-10 (IL-10). ... in a biochemical pathway that,s long been tied to disorders ... AIDS. "IL-10 production has to be kept in a ...
Cached Biology News:Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 22 genes are important key to regulating immune response 22 genes are important key to regulating immune response 3